Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Merck MASH Asset Efinopegdutide Meets Primary Goal in Mid-Stage Trial

Summary by Seeking Alpha
Merck’s efinopegdutide hit its phase 2b MASH endpoint, showing strong liver benefits vs placebo. Read more here.

5 Articles

연합뉴스-Yonhap News Agency연합뉴스-Yonhap News Agency
Lean Right

MSD: "Hanmi Pharmaceutical's New Fatty Liver Hepatitis Drug Efficacy Confirmed in Phase 2b Clinical Trial"

(Seoul = Yonhap News) Reporter Park Sang-hyun = 'Epinofegd...', a new drug candidate for metabolic fatty liver disease (MASH) developed by Hanmi Pharmaceutical [128940] and licensed to MSD

·Seoul, Korea (the Republic of)
Read Full Article
Seeking AlphaSeeking Alpha
Lean Right

Merck MASH asset efinopegdutide meets primary goal in mid-stage trial

Merck’s efinopegdutide hit its phase 2b MASH endpoint, showing strong liver benefits vs placebo. Read more here.

·Ra'anana, Israel
Read Full Article
Joplin GlobeJoplin Globe
+2 Reposted by 2 other sources
Center

Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis

RAHWAY, N.J.--(BUSINESS WIRE)--Nov 9, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Monday, November 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Merck icon

Merck

Rahway icon

Rahway

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal